The protein encoded by this gene is a member of the CMGC family of serine/threonine protein kinases. This kinase is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression and G1/S transition. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor protein Rb. Altered expression of this gene has been observed in multiple human cancers. A mutation in this gene resulting in reduced cell proliferation, and impaired cell motility and polarity, and has been identified in patients with primary microcephaly. [provided by RefSeq, Aug 2017]
Overall distribution
Tissue specific distribution
Expression restricted in 1 cancer type(s)
Overall distribution
Tissue specific distribution
Gscore (Amp):
2.03 (Driver)
Gscore (Del):
0.00
Recurrently amplified in 5 cancer type(s)
Overall distribution
Tissue specific distribution
Mscore:
0.02
Recurrently mutated in 1 cancer type(s)
Overall
Tissue specific
Total fusion occurrence:
7
Fusions detected in 5 cancer type(s)
Overall
Tissue specific
RNAi: STRONGLY SELECTIVE
Functional class:
Kinase (protein kinase)
JensenLab PubMed score:
390.15 (Percentile rank: 88.83%)
PubTator score:
374.93 (Percentile rank: 91.37%)
Target development/druggability level:
TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
Tractability (small molecule):
Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
